Media OutReach

Caltex Commemorates SG60 with Launch of Limited Edition National Day Picnic Sets

Published

5 months ago

10/07/2025

SINGAPORE – Media OutReach Newswire – 10 July 2025 – To celebrate Singapore’s SG60 milestone, Chevron Singapore, which operates the Caltex retail brand, has launched a limited-edition SG60 picnic set comprising a picnic box and two chairs. Designed to enrich Singaporeans’ upcoming National Day celebrations while fostering a sense of local community spirit, these unique items will be available for purchase at all 26 Caltex stations nationwide starting 11 July.

Caltex SG60 – Limited Edition National Day Picnic Sets

The picnic items feature vibrant, locally inspired designs created by the winners of Mediacorp’s Design Pompipi contest. The nationwide contest saw overwhelming participation with over 2,000 artwork entries and more than 18,000 votes, and the designs submitted showcased the spirit and diversity of Singapore through iconic symbols such as food, values, landmarks, and cultures.

Caltex’s SG60 picnic set is ideal for enjoying the highly anticipated National Day fireworks and various heartland celebrations across the island. With every minimum gross fuel spend of $60, customers can purchase:

1 Picnic Box – $12.60
1 Picnic Chair – $14.60
Bundle set (1 box + 2 chairs) – $36.60 (Save $5.20)

Each fuel transaction is limited to one item or set.

OCBC cardholders will enjoy an additional $2 off each purchase or $6 off each bundle set when they pay for their fuel with OCBC cards at Caltex stations. The SG60 picnic sets are available at all Caltex stations until 31 August 2025, or while stocks last.

In support of Community Chest’s SGSHARE, Chevron Singapore will donate $2 to the Community Chest for every purchase of an individual item (picnic box or picnic chair), or $6 for each bundle set purchased from now till 31 August. This initiative, capped at S$20,000, is part of Chevron Singapore’s efforts to support the community through meaningful partnerships.
Hashtag: #Chevron #Singapore #SG60

The issuer is solely responsible for the content of this announcement.

About Caltex Singapore

Chevron Singapore Pte. Ltd. markets the 89-year-young Caltex brand, which is Chevron’s customer-facing brand in Asia Pacific and parts of the Middle East and Africa. The Caltex retail network in Singapore consists of 26 Caltex service stations and Star Mart branded convenience stores.

All Caltex service stations accept the CaltexGO mobile payment for fuel purchases. Products such as the Caltex with Techron® with Clean & Glide Technology™ petrol, Caltex Diesel with Techron® D and Havoline® motor oil are also available at all Caltex service stations. In partnership with NTUC Link, the Link Rewards Programme also enables motorists to earn 2 Linkpoints for every litre of fuel purchased at Caltex.

About Chevron

Chevron is one of the world’s leading integrated energy companies. We believe affordable, reliable and ever-cleaner energy is essential to enabling human progress. Chevron produces crude oil and natural gas; manufactures transportation fuels, lubricants, petrochemicals and additives; and develops technologies that enhance our business and the industry. We aim to grow our oil and gas business, lower the carbon intensity of our operations and grow new businesses in renewable fuels, carbon capture and offsets, hydrogen, power generation for data centers, and emerging technologies. More information about Chevron is available at www.chevron.com.

Media OutReach

MIMO: The AI-Native Storage Species Enables Desktop Scale AI Clusters With NVIDIA DGX Spark

Published

11 hours ago

12/12/2025

Media Outreach

Engineered for the AI era, MIMO delivers breakthrough metrics: 400 GB/s bandwidth, 54 million IOPS, and 40–90 μs latency—all within a form factor comparable to a large suitcase.
MIMO serves as both a high-performance data hub for large-scale GPU clusters and a flexible edge deployment platform, extending seamlessly to desktop environments where it orchestrates workflows with various DGX Spark units based on NVIDIA’s GB10 Grace Blackwell superchip.
This architecture enables independent AI clusters supporting up to 16 computing nodes within constrained environments, managing the complete workflow from large-scale pre-training and fine-tuning to production inference—effectively democratizing enterprise-grade AI capabilities for labs, edge sites, and distributed teams.

SINGAPORE –

Professor Zhang Sheng from Tsinghua University Shenzhen International Graduate School expressed a more pragmatic view: “With this solution, we finally no longer have to rely on the university’s data center. Our current annual budget alone is enough to deploy an AI cluster within our lab that better fits our needs—this will significantly boost our research efficiency both technically and operationally. It’s truly fantastic news.”

Asia Debut Marks Industry Inflection Point

Earlier at the 8th China International Import Expo (CIIE), the solution’s core—the world’s first AI-native storage system MIMO—made its strategic Asian debut. Engineered for the AI era, MIMO delivers breakthrough metrics: 400 GB/s bandwidth, 54 million IOPS, and 40–90 μs latency—all within a form factor comparable to a large suitcase.

The platform’s defining Fast-Light-Edge proposition, delivered through its breakthrough architecture, cut through the exhibition noise, generating immediate and widespread attention. MIMO earned exclusive features in top-tier media including Hong Kong Ta Kung Pao and China Securities Journal, while its product demonstration videos gained rapid traction across leading digital channels.

Addressing Foundational Challenges: Technical Dialogues That Matter

During the exhibitions, technical leaders from the United States, Spain, Singapore, Colombia, the UAE (Dubai), India, Pakistan, and Hong Kong SAR engaged in substantive dialogues with Ridger’s Asia team, raising questions that revealed systemic industry gaps:

Architectural Transformation & Strategic Positioning
“Can MIMO fundamentally replace legacy storage architectures—traditional NAS, unified, distributed, and parallel file systems—to deliver accelerated parallel training and high-concurrency inference?”
“With such exceptional performance, would deploying MIMO for traditional enterprise applications represent strategic overinvestment or forward-looking infrastructure?”

Mobile Deployment & Borderless Operations
“MIMO’s suitcase-sized footprint suggests unprecedented mobility. Can it truly accompany research teams globally like standard equipment? How does it maintain operational continuity across jurisdictions? What’s the customs protocol for such ‘technical luggage’?”

Seamless Integration & Global Accessibility
“In scenarios with unnetworked AI servers, can MIMO rapidly establish dedicated training environments with true plug-and-play functionality?”
“Does MIMO integrate transparently with existing AI infrastructure and software stacks without requiring modifications?”
“Beyond Asia-Pacific, what’s the procurement pathway for MIMO? Which currencies and payment methods are accommodated?”

Architectural Breakthrough: Redefining What’s Possible

Addressing these operational realities, Ridger demonstrated MIMO’s system-level value—transcending its role as a storage device to become an architectural cornerstone. MIMO serves as both a high-performance data hub for large-scale GPU clusters and a flexible edge deployment platform, extending seamlessly to desktop environments where it orchestrates workflows with various DGX Spark units based on NVIDIA’s GB10 Grace Blackwell superchip.

Notably, eight global OEM partners—including Dell, HPE, Lenovo, xFusion, H3C, MSI, GIGABYTE, and Acer—have concurrently launched Spark versions based on NVIDIA’s GB10 Grace Blackwell superchip, creating a robust compatibility foundation for MIMO’s ecosystem integration.

This architecture enables independent AI clusters supporting up to 16 computing nodes within constrained environments, managing the complete workflow from large-scale pre-training and fine-tuning to production inference—effectively democratizing enterprise-grade AI capabilities for labs, edge sites, and distributed teams.

As Zhu Ting, an industry observer from Beijing, noted: “This represents the ‘IBM PC moment’ for AI infrastructure—transforming specialized capability into accessible utility.”

Market Validation Through Early Adoption

Market response has been decisive. Following the exhibitions, pioneering organizations across pathological image foundation model development, legal-tech innovation, industrial visual inspection, and naked-eye 3D content production have joined Ridger’s Early Access program, validating the architecture’s transformative potential in real-world operational contexts.

Global Rollout: Accelerating Accessibility

Responding to accelerating global demand, Ridger confirmed the imminent launch of the complete MIMO portfolio and optimized solution bundles for specific DGX Spark configurations through the Ridger Official Global Store. Designed as a frictionless procurement channel, the platform will support diverse payment options including multiple fiat currencies and cryptocurrencies—streamlining access to advanced AI infrastructure.

Organizations seeking deeper understanding of MIMO and its integrated lightweight AI solution with DGX Spark are invited to connect with Ridger team or its strategic partner, NVIDIA Elite Solution Partner SinoInfo.
Hashtag: #Technology #ESG #AI #GPU #Enterprise #Finance #Storage #Flash #Compute #DGX-Spark #NVIDIA #AI-Lab #GDS #NAS #AI-Native

https://ridger.tech/
https://www.linkedin.com/company/ridger/
https://www.youtube.com/@ridgertech

The issuer is solely responsible for the content of this announcement.

Ridger

Ridger is a global technology pioneer building next-generation computing & storage infrastructure for the AI era. Born in the East and operating worldwide, Ridger challenges conventional paths to create new technological paradigms.

The team unites seasoned experts from global storage leaders with visionary AI architects, all driven by a shared mission to democratize cutting-edge technology, rejects incremental improvements and hollow prestige, focusing exclusively on foundational breakthroughs that deliver tangible value and sustainable impact.

From architecture to implementation and from service to empowerment, Ridger provides end-to-end solutions that help clients worldwide ascend to their highest summits.

Media OutReach

Johnson & Johnson and Asia Pacific Patient Advocacy Group Leaders Unite to Strengthen Shared Decision-Making in Lung Cancer Care

Published

12 hours ago

12/12/2025

Media Outreach

Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction with their treatments, with 90% of lung cancer patients in Japan wanting to play an active role in their treatment decisions[1]

J&J deepens its commitment to patient empowerment in Asia Pacific by launching J&J withMe, a new patient portal offering tailored patient resources, and co-driving market-specific initiatives with patient advocacy groups

SINGAPORE – Media OutReach Newswire – 11 December 2025 – Johnson & Johnson announced the next phase of The 3rd Opinion campaign across Asia Pacific, focused on championing shared decision-making between lung cancer patients and healthcare professionals through events and stakeholder engagements at ESMO Asia 2025 in Singapore.

At a Patient Reception on 6^th December 2025, 20 leaders from 17 patient advocacy groups from across Asia Pacific, Europe and the United States shared their support for the need to strengthen shared decision-making. On December 7, 2025, the ESMO Asia 2025 Symposium, ‘Advancing EGFRm NSCLC Treatment Through Shared Decision-Making’ highlighted the role of healthcare professionals not only in making sense of the data but also in helping patients and their families navigate complex decision-making.

“High prevalence in Asia of certain NSCLC mutations makes the choice of first-line therapy absolutely critical. Treatment decisions must balance clinical objectives with patient values — weighing disease biology, survival prospects, durable disease control and the tradeoffs of side effects. That’s why shared decision-making is essential: clinicians should present all appropriate treatment options, so the final choice is collaborative and aligned with each patient’s goals,” said Professor Zhu Zhengfei, Director of the Radiation Oncology Department, Fudan University Shanghai Cancer Center.

“When lung cancer patients are empowered to speak up and understand their options, they are more likely to continue the treatment and their dignity is preserved. Initiatives like ‘The 3rd Opinion’ are vital for fostering truly patient-centered partnerships between people living with cancer and their healthcare teams,” noted Ms. Liu Yiting, Marketing & Branding Director, China MeetHealth Mi-Jian Patient Community.

“The shared commitment validates what many people living with lung cancer have long expressed: shared decision making is essential. From our experience supporting patients, meaningful conversations with clinicians help acknowledge patients’ experiences, address their concerns, and preserving their hopes,” added Mr. Jung-Il Cho, Chairman of Korea Lung Cancer Patients Association.

Our commitment comes off the back of a recent patient survey revealing that 90% of Japanese lung cancer patients want to play an active role in their treatment decisions. The survey also found that shared decision-making, where physicians and patients jointly compare treatment options and decide together, is the strongest driver of treatment satisfaction.¹

To bridge the gap between patients’ desire to engage in shared decision making and their lack of practical support, J&J has launched “J&J withMe”, an online hub that equips lung cancer patients and caregivers with tailored toolkits and conversation guides to prepare for consultations and make informed, personalized treatment decisions.

Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific said, “The 3rd Opinion truly puts patients at the center of care. As part of our deep commitment to address patients’ unmet needs, we will continue partnering with patient advocacy groups and healthcare professionals to help patients to find their voice and the moment when medical advice meets what truly matters to patients.”

In recognition of diverse cultural and clinical norms across Asia Pacific, J&J has also rolled out tailored market activations in collaboration with local patient advocacy groups:

Provision of patient resources such as the “Lung Cancer Book of Answers” in China, ‘Value of Time’ video for patients in Japan, and educational assets in India and Australia/New Zealand;
Digital and social media engagement featuring patients and creators discussing the importance of shared decision-making across Singapore, Malaysia, Philippines, Thailand, and Vietnam;
Event engagement via the establishment of a patient advisory board in India;
Corporate Social Responsibility program with a lung cancer patient group in Korea, bringing employees and patients together to better understand the disease burden of patients and strengthen emotional support for the patient community.

###

About the 3^rd Opinion

“The 3rd Opinion”, the patient’s own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.

About Non-Small Cell Lung Cancer

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[1]^, [2] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[3] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[4] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[5]^{, [6],[7],[8],[9],[10]}EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[11] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.[12]^,[13] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[14] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[15]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[16].

[1] Johnson & Johnson lung cancer patient quantitative survey conducted in Japan, 2025

[2] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[3] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[4] Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

[5] Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[6] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[7] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[8] Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.

[9] Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[10] Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.

[11] Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.

[12] American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed March 2025.

[13] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.

[14] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65

[15] Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.

[16] Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[17] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, 2024.

Hashtag: #Johnson&Johnson

The issuer is solely responsible for the content of this announcement.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.

Johnson & Johnson Innovative Medicine Asia Pacific, a division of Johnson & Johnson International (Singapore) Pte. Ltd is a Johnson & Johnson company.

Media OutReach

Skychakra Global Capital Strategy Upgrade: Advancing Cross-Border Listings and RWA Ecosystem

Published

24 hours ago

11/12/2025

Media Outreach

HONG KONG SAR – Media OutReach Newswire – 11 December 2025 – Skychakra Group recently held a grand inauguration ceremony at the Hong Kong International Center, announcing the official acceleration of its globalization strategy. With a mission to “enhance individual energy, empower enterprise growth, and promote asset capitalization,” Skychakra simultaneously launched three major international initiatives: a cross-border listing incubation system, an RWA (Real World Assets) technology ecosystem, and the international upgrade of mind-body energy science, building a new economic ecosystem that spans technology, industry, and capital.

As a global hub for innovation and capital, Hong Kong serves as a significant gateway for the activation of Skychakra’s global strategy. This inauguration not only symbolizes the completion of the facility but also marks the comprehensive rollout of Skychakra’s international layout.

Official Launch of Cross-Border Listing Incubation Center

During the inauguration, Skychakra announced the establishment of a cross-border listing incubation center, led by a professional team qualified with SEC, PCAOB, and FINRA credentials, boasting over a hundred projects in cross-border listings. The service scope includes U.S. stocks, Hong Kong stocks, and SPACs. Unlike traditional investment banks and financial advisors, Skychakra offers a “full-link” service for enterprise capitalization, encompassing red-chip structure setup, financial and audit compliance, SEC and Hong Kong Stock Exchange filing guidance, dual-path IPO/SPAC design, market value management, enterprise internationalization guidance, and digital upgrades.

Originally planning to sign contracts for four companies at the conference, Skychakra exceeded expectations by signing 12, demonstrating its strong appeal and industry influence in cross-border listings and capital operations.

RWA Technology Ecosystem: Making Enterprise Assets Visible to the Financial System

Real World Assets (RWA) are becoming the core of global financial transformation. From BlackRock’s launch of tokenized funds to Hong Kong and Singapore incorporating RWA into financial infrastructure, RWAs are transitioning from concept to large-scale implementation. Skychakra emphasizes that small and medium-sized enterprises face common challenges such as lack of recognition for their assets within the financial system, difficulties in cross-border financing, and a lack of transparency in asset value.

The Skychakra RWA ecosystem will provide enterprises with: tokenizable asset identification, asset structuring and entitlement, on-chain mapping and minting, cross-border compliance design, global issuance and liquidity channels, and on-chain risk control and transparent tracking. The core value of RWA lies in reducing friction for enterprises in connecting to global capital, enhancing asset liquidity and valuation potential.

A Holistic Growth Model: “From People to Enterprises, From Enterprises to Capital”

Skychakra’s differentiated advantage stems from its foundational logic of “starting with people.” The Skychakra energy courses utilize scientific equipment to measure energy fields, emotional frequencies, and meridian states, assisting individuals in enhancing stability, insight, and decision-making abilities.

Based on this foundation, Skychakra constructs three major systems:

1. Enterprise Growth System: Enhancing organizational capabilities, introducing international business, and providing capital operation guidance.

2. Capitalization System: Building global financing capabilities through listings and RWA structures.

3. Asset Digitalization System: Making enterprise value quantifiable, verifiable, and tradable.

These three systems dynamically interact in a spiral structure, forming Skychakra’s unique full-link growth ecosystem.

Conclusion: Global Layout for Greater International Influence

The inauguration of Skychakra’s Hong Kong International Center signifies the official implementation of the group’s globalization strategy. Looking forward, the focus will be on Hong Kong as the core, with Asia as the main axis, while establishing deep collaborations with the North American and Middle Eastern markets. Through this global layout, Skychakra is creating a new organizational model that transcends regions, industries, and capital, enabling enterprises to achieve value flow in the global market and allowing more Asian companies to gain a stronger voice on the international stage.

Hashtag: #Skychakra

The issuer is solely responsible for the content of this announcement.